Legend: : Special Mention  : Important : Very Important : Key Development |
| |
 |
A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study.
Uitdehaag MJ, Hooft JE, Verschuur EM, Repici A, Steyerberg EW, Fockens P, Kuipers EJ, Siersema PD, Gastrointest Endosc. 2009 Jul 27; |
| |
Hyperdynamic upper esophageal sphincter pressure: a manometric observation in patients reporting globus sensation.
Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE, Am J Gastroenterol. 2009 Feb;104(2):289-98 |
 |
Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia.
Boeckxstaens GE, Annese V, des Varannes SB, Chaussade S, Costantini M, CuttittaA, Elizalde JI, Fumagalli U, Gaudric M, Rohof WO, Smout AJ, Tack J, ZwindermanAH, Zaninotto G, Busch OR; European Achalasia Trial Investigators., N Engl J Med. 2011 May 12;364(19):1807-16. |
| |
Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: theLOTUS randomized clinical trial.
Galmiche JP, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, Långström G, LindT, Lundell L; LOTUS Trial Collaborators., JAMA. 2011 May 18;305(19):1969-77. |
| |
Effects of lesogaberan on reflux and lower esophageal sphincter function inpatients with gastroesophageal reflux disease.
Boeckxstaens GE, Beaumont H, Mertens V, Denison H, Ruth M, Adler J, Silberg DG,Sifrim D., Gastroenterology. 2010 Aug;139(2):409-17. Epub 2010 May 5. |
| |
Inhibition of transient lower esophageal sphincter relaxation in GERD: willlesogaberan advance the field?
Falk GW., Gastroenterology. 2010 Aug;139(2):377-9. Epub 2010 Jun 23. |
| |
Pharmacological dependency in chronic treatment of gastroesophageal refluxdisease: a randomized controlled clinical trial.
van der Velden AW, de Wit NJ, Quartero AO, Grobbee DE, Numans ME., Digestion. 2010;81(1):43-52. Epub 2009 Dec 22. |
 |
A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patientswith GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Björck K, Karlsson M,Denison H., Gut. 2011 Sep;60(9):1182-8. Epub 2011 Mar 14. |
| |
Randomized comparison of three palliative regimens including brachytherapy,photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a)(Revised II).
Rupinski M, Zagorowicz E, Regula J, Fijuth J, Kraszewska E, Polkowski M, Wronska E, Butruk E., Am J Gastroenterol. 2011 Sep;106(9):1612-20. doi: 10.1038/ajg.2011.178. Epub 2011Jun 14. |
| |
A prospective study to compare a symptom-based reflux disease questionnaire to48-h wireless pH monitoring for the identification of gastroesophageal reflux(revised 2-26-11).
Lacy BE, Chehade R, Crowell MD., Am J Gastroenterol. 2011 Sep;106(9):1604-11. doi: 10.1038/ajg.2011.180. Epub 2011Jun 21. |
| |
Influence of common cardiac drugs on gastroesophageal reflux disease: multicenterquestionnaire survey.
Nakaji G, Fujihara M, Fukata M, Yasuda S, Odashiro K, Maruyama T, Akashi K., Int J Clin Pharmacol Ther. 2011 Sep;49(9):555-62. |
| |
Budesonide is effective in adolescent and adult patients with active eosinophilicesophagitis.
Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, Bussmann C, BeglingerC, Schoepfer A, Simon HU., Gastroenterology. 2010 Nov;139(5):1526-37, 1537.e1. Epub 2010 Aug 1. |
| |
Arbaclofen placarbil decreases postprandial reflux in patients withgastroesophageal reflux disease.
Gerson LB, Huff FJ, Hila A, Hirota WK, Reilley S, Agrawal A, Lal R, Luo W,Castell D., Am J Gastroenterol. 2010 Jun;105(6):1266-75. Epub 2009 Dec 29. |
| |
An antireflux anastomosis following esophagectomy: a randomized controlled trial.
Aly A, Jamieson GG, Watson DI, Devitt PG, Ackroyd R, Stoddard CJ., J Gastrointest Surg. 2010 Mar;14(3):470-5. Epub 2009 Dec 9. |
| |
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilicoesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C,Smith DA, Patel J, Byrne M, Simon HU., Gut. 2010 Jan;59(1):21-30. |
| |
Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux.
JM Wo, J Koopman, SP Harrell, K Parker, W Winstead, E Lentsch, Am J Gastroenterol. 2006 Sep:1972-8; quiz 2169 |
| |
Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: A randomized, sham-controlled trial.
R Rothstein, C Filipi, K Caca, R Pruitt, K Mergener, A Torquati, G Haber, Y Chen, K Chang, D Wong, J Deviere, D Pleskow, C Lightdale, A Ades, R Kozarek, W Richards, A Lembo, Gastroenterology. 2006 Sep:704-12 |
| |
The rise and fall (and rise?) of endoscopic anti-reflux procedures.
NJ Shaheen, Gastroenterology. 2006 Sep:952-4 |
| |
Randomised clinical trial: efficacy of the addition of a prokinetic, mosapridecitrate, to omeprazole in the treatment of patients with non-erosive refluxdisease - a double-blind, placebo-controlled study.
Miwa H, Inoue K, Ashida K, Kogawa T, Nagahara A, Yoshida S, Tano N, Yamazaki Y,Wada T, Asaoka D, Fujita T, Tanaka J, Shimatani T, Manabe N, Oshima T, Haruma K, Azuma T, Yokoyama T; Japan TREND study group., Aliment Pharmacol Ther. 2011 Feb;33(3):323-32. doi:10.1111/j.1365-2036.2010.04517.x. Epub 2010 Dec 1. |
| |
BMI is superior to symptoms in predicting response to proton pump inhibitor:randomised trial in patients with upper gastrointestinal symptoms and normalendoscopy.
Fletcher J, Derakhshan MH, Jones GR, Wirz AA, McColl KE., Gut. 2011 Apr;60(4):442-8. Epub 2010 Dec 15. |
| |
Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
Miehlke S, Löbe S, Madisch A, Kuhlisch E, Laass M, Grossmann D, Knoth H, Morgner A, Labenz J., Aliment Pharmacol Ther. 2011 Feb;33(4):471-6. doi:10.1111/j.1365-2036.2010.04544.x. Epub 2010 Dec 22. |
| |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleepdisturbances in patients with symptomatic GERD.
Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, Pilmer BL, Perez MC., Am J Gastroenterol. 2011 Mar;106(3):421-31. Epub 2011 Jan 11. |
| |
Adjunctive functional pharyngeal electrical stimulation reverses swallowingdisability after brain lesions.
Jayasekeran V, Singh S, Tyrrell P, Michou E, Jefferson S, Mistry S, Gamble E,Rothwell J, Thompson D, Hamdy S., Gastroenterology. 2010 May;138(5):1737-46. Epub 2010 Feb 2. |
| |
The effect of esomeprazole 20 mg twice daily on acoustic and perceptionparameters of the voice in laryngopharyngeal reflux.
Fass R, Noelck N, Willis MR, Navarro-Rodriguez T, Wilson K, Powers J,Barkmeier-Kraemer JM., Neurogastroenterol Motil. 2010 Feb;22(2):134-41, e44-5. Epub 2009 Sep 9. |
| |
A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures.
JI Ramage Jr, A Rumalla, TH Baron, NL Pochron, AR Zinsmeister, JA Murray, ID Norton, N Diehl, Y Romero, Am J Gastroenterol. 2005 Nov:2419-25 |
| |
Differences in ERK activation in squamous mucosa in patients who have gastroesophageal reflux disease with and without Barrett's esophagus.
RF Souza, KL Shewmake, Y Shen, RD Ramirez, JS Bullock, CL Hladik, EL Lee, LS Terada, SJ Spechler, Am J Gastroenterol. 2005 Mar:551-9 |
| |
Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial.
MP Schwartz, H Wellink, HG Gooszen, JM Conchillo, M Samsom, AJ Smout, Gut. 2007 Jan:20-8 |
| |
Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.
V Tolia, PR Bishop, VM Tsou, D Gremse, EF Soffer, GM Comer, Members of the 322 Study Group, J Pediatr Gastroenterol Nutr. 2006 Apr:384-91 |
| |
New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial.
EM Verschuur, A Repici, EJ Kuipers, EW Steyerberg, PD Siersema, Am J Gastroenterol. 2008 Feb:304-12 |
| |
Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial.
J Devière, G Costamagna, H Neuhaus, W Voderholzer, H Louis, A Tringali, M Marchese, T Fiedler, P Darb-Esfahani, B Schumacher, Gastroenterology. 2005 Mar:532-40 |
| |
Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.
PO Katz, GG Ginsberg, PE Hoyle, MB Sostek, JT Monyak, DG Silberg, Aliment Pharmacol Ther. 2007 Mar 1:617-28 |
| |
Twelve months' follow-up after treatment with the EndoCinch endoscopic technique for gastro-oesophageal reflux disease: a randomized, placebo-controlled study.
M Montgomery, B Håkanson, O Ljungqvist, B Ahlman, A Thorell, Scand J Gastroenterol. 2006 Dec:1382-9 |
| |
Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial.
J Wenner, F Johnsson, J Johansson, S Oberg, Am J Gastroenterol. 2007 Feb:239-45 |
| |
The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with adual delayed release formulation, in patients with gastro-oesophageal refluxdisease.
Dabholkar AH, Han C, Paris MM, Perez MC, Atkinson SN, Peura DA., Aliment Pharmacol Ther. 2011 Feb;33(3):366-77. doi:10.1111/j.1365-2036.2010.04519.x. Epub 2010 Nov 30. |
| |
The gain in quality-adjusted life months by switching to esomeprazole in thosewith continued reflux symptoms in primary care: EncomPASS--a cluster-randomizedtrial.
Moayyedi P, Armstrong D, Hunt RH, Lei Y, Bukoski M, White RJ., Am J Gastroenterol. 2010 Nov;105(11):2341-6. Epub 2010 Sep 14. |
| |
Efficacy of three different dosages of esomeprazole in the long-term managementof reflux disease: a prospective, randomized study, using the wireless Bravo pHsystem.
Vasiliadis KV, Viazis N, Vlachogiannakos J, Sgouros SN, Stefanidis G,Archimandritis A, Karamanolis DG., Am J Gastroenterol. 2010 Feb;105(2):308-13. Epub 2009 Oct 6. |
| |
Proton pump inhibitor influence on reflux in Barrett's oesophagus.
Smythe A, Troy GP, Ackroyd R, Bird NC, Eur J Gastroenterol Hepatol. 2008 Sep;20(9):881-7 |
| |
A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia.
M Conio, A Repici, G Battaglia, G De Pretis, L Ghezzo, M Bittinger, H Messmann, JF Demarquay, S Blanchi, M Togni, R Conigliaro, R Filiberti, Am J Gastroenterol. 2007 Dec:2667-77 |
| |
Acid challenge to the esophageal mucosa: effects on local nitric oxide formation and its relation to epithelial functions.
M Bove, M Vieth, A Casselbrant, L Ny, L Lundell, M Ruth, Dig Dis Sci. 2005 Apr:640-8 |
| |
Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
C Wilder-Smith, T Lind, C Lundin, E Nauclér, C Nilsson-Pieschl, K R&oeig;hss, Scand J Gastroenterol. 2007 Feb:157-64 |
| |
Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
PB Miner Jr, LD Allgood, JM Grender, Aliment Pharmacol Ther. 2007 Jan 1:103-9 |
| |
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime do
PO Katz, FK Koch, ED Ballard, RG Bagin, TC Gautille, GC Checani, DL Hogan, VS Pratha, Aliment Pharmacol Ther. 2007 Jan 15:197-205 |
| |
Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease.
DC Metz, PB Miner, DM Heuman, Y Chen, M Sostek, Aliment Pharmacol Ther. 2005 Nov 1:813-21 |
| |
Comparison of 2 interventions for liquid aspiration on pneumonia incidence: a randomized trial.
Robbins J, Gensler G, Hind J, Logemann JA, Lindblad AS, Brandt D, Baum H, Lilienfeld D, Kosek S, Lundy D, Dikeman K, Kazandjian M, Gramigna GD, McGarvey-Toler S, Miller Gardner PJ, Ann Intern Med 2008 Apr 1;148(7):509-18 |
| |
Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
E Bj&oeig;rnsson, H Abrahamsson, M Simrén, N Mattsson, C Jensen, P Agerforz, A Kilander, Aliment Pharmacol Ther. 2006 Sep 15:945-54 |
| |
Effect of dietary sodium chloride on gastro-oesophageal reflux: a randomized controlled trial.
MC Aanen, AJ Bredenoord, AJ Smout, Scand J Gastroenterol. 2006 Oct:1141-6 |
| |
Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
P Bytzer, A Morocutti, P Kennerly, M Ravic, N Miller, ROSE Trial Investigators, Scand J Gastroenterol. 2006 Oct:1132-40 |
| |
Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux.
Zheng Z, Margolis KL, Liu S, Tinker LF, Ye W, Women's Health Initiative Investigators, Gastroenterology. 2008 Jul;135(1):72-81 |
| |
Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE
KL Goh, R Benamouzig, P Sander, T Schwan, EMANCIPATE, Eur J Gastroenterol Hepatol. 2007 Mar:205-11 |
| |
Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
PJ Kahrilas, P Miner, J Johanson, L Mao, L Jokubaitis, S Sloan, Dig Dis Sci. 2005 Nov:2009-18 |
| |
Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
H Miwa, M Sasaki, T Furuta, T Koike, Y Habu, M Ito, Y Fujiwara, T Wada, A Nagahara, M Hongo, T Chiba, Y Kinoshita, ACID-RELATED SYMPTOM (ARS) RESEARCH GROUP, Aliment Pharmacol Ther. 2007 Jul 1:69-77 |
| |
Endoluminal gastroplication for the treatment of gastroesophageal reflux disease: a 2-year prospective pilot study from Taiwan.
Liao CC, Lee CL, Lin BR, Bai CH, Hsieh YH, Wu CH, Gostout CJ, J Gastroenterol Hepatol 2008 Mar;23(3):398-405 |
| |
Endoscopic full-thickness plication (Plicator) with two serially placed implants improves esophagitis and reduces PPI use and esophageal acid exposure.
A Horiuchi, Y Nakayama, H Fujii, M Kajiyama, Endoscopy 2008 Mar;40(3):173-8 |
| |
Endoscopic holder-assisted percutaneous endoscopic gastrostomy placement: results of a prospective, randomized comparison study.
A Horiuchi, Y Nakayama, H Fujii, M Kajiyama, Gastrointest Endosc. 2006 Oct:627-31 |
| |
Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized-controlled trial.
J Mikaeli, F Bishehsari, G Montazeri, M Mahdavinia, M Yaghoobi, S Darvish-Moghadam, F Farrokhi, S Shirani, A Estakhri, R Malekzadeh, Aliment Pharmacol Ther. 2006 Sep 15:983-9 |
| |
Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial.
V Pratha, DL Hogan, RB Lynn, B Field, DC Metz, Dig Dis Sci. 2006 Sep:1595-601 |
| |
Long-term outcome is worse after laparoscopic than after conventional Nissen fundoplication.
T Franzén, B Anderberg, M Wirén, KE Johansson, Scand J Gastroenterol. 2005 Nov:1261-8 |
| |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
S Mine, T Iida, T Tabata, H Kishikawa, Y Tanaka, J Gastroenterol Hepatol. 2005 Sep:1365-70 |
| |
Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment.
Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V, Am J Gastroenterol 2008 Feb;103(2):267-75 |
| |
Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison.
BA Jobe, JG Hunter, EY Chang, CY Kim, GM Eisen, JD Robinson, BS Diggs, RW O'Rourke, AE Rader, P Schipper, DA Sauer, JH Peters, DA Lieberman, CD Morris, Am J Gastroenterol. 2006 Dec:2693-703 |
| |
On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial.
T Scholten, CP Dekkers, K Schutze, T K&oeig;rner, M Bohuschke, G Gatz, Digestion. 2005:76-85 |
| |
Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagi
D Hogan, V Pratha, D Riff, S Ducker, H Schwartz, E Soffer, W Wang, N Rath, GM Comer, Aliment Pharmacol Ther. 2007 Jul 15:249-56 |
| |
Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project.
RF Harvey, JA Lane, LJ Murray, IM Harvey, JL Donovan, P Nair, Bristol Helicobacter Project, BMJ. 2004 Jun 12:1417 |
| |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
O Diav-Citrin, J Arnon, S Shechtman, C Schaefer, MR van Tonningen, M Clementi, M De Santis, E Robert-Gnansia, E Valti, H Malm, A Ornoy, Aliment Pharmacol Ther. 2005 Feb 1:269-75 |
| |
White wine and beer induce gastro-oesophageal reflux in patients with reflux disease.
C Pehl, B Wendl, A Pfeiffer, Aliment Pharmacol Ther. 2006 Jun 1:1581-6 |
| Supplementary evidence: |
| |
A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease.
KD Bardhan, A Achim, T Riddermann, B Pfaffenberger, Aliment Pharmacol Ther. 2007 Jun 15:1461-9 |
| |
A randomised prospective comparison of the Flamingo Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third oesophageal carcinoma.
T Sabharwal, MS Hamady, S Chui, S Atkinson, R Mason, A Adam, Gut. 2003 Jul:922-6 |
| |
An ongoing randomized clinical trial in dysphagia.
J Robbins, J Hind, J Logemann, J Commun Disord. 2004 Sep-Oct:425-35 |
| |
Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment.
NB Vakil, B Traxler, D Levine, Clin Gastroenterol Hepatol. 2004 Aug:665-8 |
| |
Effectiveness of esophageal dilation in relieving nonobstructive esophageal dysphagia and improving quality of life.
K Lavu, TP Mathew, A Minocha, South Med J. 2004 Feb:137-40 |
| |
Empiric Dilation in Non-obstructive Dysphagia.
JS Olson, DA Lieberman, A Sonnenberg, Dig Dis Sci. 2008 May:1192-7 |
| |
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
YC Lee, JT Lin, HP Wang, HM Chiu, MS Wu, J Gastroenterol Hepatol. 2007 Aug:1286-92 |
| |
Prospective, randomized outcome study of endoscopy versus modified barium swallow in patients with dysphagia.
Y Finkelstein, Laryngoscope. 2002 Feb:409-12 |
| |
Rehabilitation of swallowing by exercise in tube-fed patients with pharyngeal dysphagia secondary to abnormal UES opening.
R Shaker, C Easterling, M Kern, T Nitschke, B Massey, S Daniels, B Grande, M Kazandjian, K Dikeman, Gastroenterology. 2002 May:1314-21 |
| |
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial.
MY Homs, EW Steyerberg, WM Eijkenboom, HW Tilanus, LJ Stalpers, JF Bartelsman, JJ van Lanschot, HK Wijrdeman, CJ Mulder, JG Reinders, H Boot, BM Aleman, EJ Kuipers, PD Siersema, Lancet. 2004 Oct 23-29:1497-504 |
| |
The value of scintigraphy in the evaluation of oropharyngeal dysphagia.
M Argon, Y Secil, U Duygun, I Aydogdu, K Kocacelebi, H Ozkilic, C Ertekin, Eur J Nucl Med Mol Imaging. 2004 Jan:94-8 |
| |
Theophylline-improved swallowing reflex in elderly nursing home patients.
T Ebihara, S Ebihara, T Okazaki, H Takahashi, A Wantando, H Yasuda, H Sasaki, J Am Geriatr Soc. 2004 Oct:1787-8 |
| |
Value of radiotherapy and chemotherapy after SEMS implantation operation in patients with malignant esophageal stricture
YT Han, L Peng, Q Fang, Q Li, Ai Zheng. 2004 Jun:682-4 |